Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05431985
Other study ID # 2015 LAPORTE
Secondary ID
Status Completed
Phase
First received
Last updated
Start date January 1, 2017
Est. completion date July 1, 2019

Study information

Verified date June 2022
Source University Hospital, Clermont-Ferrand
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Objective: Analgesic Opioids misuse among patients with chronic pain ranges from 0% to 50%. The general practitioner is the first prescriber of opioid analgesics Our objective was to validate in primary care the POMI (Prescription Opioid Misuse Index) to identify the misuse of AOs. Study Setting: Patients with chronic pain, taking AOs for at least 3 months, and followed in general practice. Study design: Psychometric study Data Collection/Extraction methods: Eligible patients followed in general practice responded to the POMI: Test phase. They then responded after 2 weeks: the retest. The gold standard used was the DSM-V.


Description:

Chronic pain represents a major problem in terms of individual, quality of life, and collective impact: cost generated by delays in treatment and care. The prevalence of chronic pain among the general population varies from 10.1 to 55.2%. In the front line, general practitioners (GP) are at the heart of treating pain : pain represent 43% of the reasons for the consultation, 24% of these being for chronic pain. More than half of these patients had exclusive care through their GP. The others are followed up in a pain assessment and treatment center. In 2015, nearly one in five French people (17,1%) of French people have taken opioid treatment. The risk of opioid use disorder secondary to opioid analgesics among patients suffering from chronic pain varies from 0% to 50%. American recommendations advocate periodic surveillance of this opioid use disorder depending on the patient's risk factors, when chronic opioid analgesics are prescribed. The French "Limoges" recommendations also mention a systematic search for signs of psychological dependence during treatment and state that treatment with strong opioids should be stopped in the event of misuse, abuse or addiction. They recommend, on each examination, the investigation for signs of misuse or psychological dependence (characterised by craving) as ways of monitoring that strong opioids are being correctly used in chronic osteo-articular pain. Identifying the misuse is a way of optimising their benefit/risk ratio The difficulty in establishing the prevalence of misuse is due to a lack of standardization of studies and the lack of consensus in the use of assessment tools. Several tools are available internationally. The only diagnostic criteria available are those of the DSM-5 (Fifth Edition of the Diagnostic and Statistical Manual of Mental Disorders) or the ICD-10 which overestimate this prevalence notably by the presence of frequent tolerance and withdrawal criteria for these patients, in the absence of misuse or addiction. Today, no screening scale has been validated in France for primary care, but recently, the authors have validated the POMI scale in French to screen the patients specifically followed in pain clinic and presenting a misuse behavior of their opioid analgesic treatment. In 2015, treatment initiation was carried out by a GP in 59.1% of cases for weak opioid and 62.9% of cases for strong opioids and by a hospital doctor for 20.1% and 21% respectively7. Currently, no scale was validated in primary care. A scale validated in French would make it possible to standardize these screening practices and secure prescription both from the point of view of the doctor and of the patient. Furthermore, this absence of a validated tool in French is proving to be an obstacle to the development of true pharmaco-epidemiological studies on the prevalence of the opioids misuse. The originality of this study is to assess the clinical relevance of the french transcultural validation of the POMI scale in primary care in order to ensure an appropriate and relevant use by all health professionals and to allow large-scale screening for the misuse behavior of analgesic opioids. The aim of the study was a validation of the French version of the Prescription Opioid Misuse Index - POMI patients with chronic pain in general practitioners setting. Secondary objective - To study the profile of participants with misuse of opioid analgesics. - To compare the results of this study with the previous study on patients followed in pain clinic.


Recruitment information / eligibility

Status Completed
Enrollment 160
Est. completion date July 1, 2019
Est. primary completion date March 1, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patients aged 18 and over, - Patients with chronic pain for at least 6 months, - Patients with a prescription from the GP of at least one Opioid analgesic drug taken daily for at least the previous 3 months, - Patients registered with the French insurance system. Exclusion Criteria: - Discontinuation of opioid prescriptions on the test phase day (no Retest possible), - Patients in the process of withdrawal (risk of having been withdrawn during the Retest phase), - Patients unable to complete the questionnaire alone, - Patients who are monitored by a pain clinic or addiction centre, - Patients with ongoing cancer, - Patients refusing to participate.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
France CHU Clermont-Ferrand, UMR INSERM 1107, NEURO-DOL Clermont-Ferrand
France Département de médecine Générale, Facultés de Médecine de Clermont-Ferrand Clermont-Ferrand
France Département de médecine générale, Lyon Lyon
France Département de médecine générale, Faculté de médecine, Montpellier Montpellier
France Département de médecine générale, Faculté de médecine, Toulouse Toulouse

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Clermont-Ferrand

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Prescription Opioid Misuse Index - POMI Prescription Opioid Misuse Index (POMI) scale was developed in the United States to assess the oxycodone misuse. This scale was validated among 137 subjects recruited from pain clinics, addiction treatment programs, jails, or private medical practice. The POMI is an 8 point self-assessment scale each numbered 0 (absence) or 1 (presence). The sum of point is used to calculate a score (between 0 and 8) and a score of more or equal to 2 is considered as positive and describe a misuse. at inclusion
Primary Prescription Opioid Misuse Index - POMI Prescription Opioid Misuse Index (POMI) scale was developed in the United States to assess the oxycodone misuse. This scale was validated among 137 subjects recruited from pain clinics, addiction treatment programs, jails, or private medical practice. The POMI is an 8 point self-assessment scale each numbered 0 (absence) or 1 (presence). The sum of point is used to calculate a score (between 0 and 8) and a score of more or equal to 2 is considered as positive and describe a misuse. 2 weeks after the first completion
Secondary Sociodemographic characteristics GPs asked patients about sociodemographic data (age, gender, family status, professional status); medical and family medical history; history of psychiatric problem, substance use and abuse. once, at inclusion
See also
  Status Clinical Trial Phase
Completed NCT01659073 - Using Perfusion MRI to Measure the Dynamic Changes in Neural Activation Associated With Caloric Vestibular Stimulation N/A
Recruiting NCT05914311 - Use of Dermabond in Mitigation of Spinal Cord Stimulation (SCS) Trial Lead Migration N/A
Recruiting NCT05422456 - The Turkish Version of Functional Disability Inventory
Enrolling by invitation NCT05422443 - The Turkish Version of Pain Coping Questionnaire
Completed NCT05057988 - Virtual Empowered Relief for Chronic Pain N/A
Completed NCT04385030 - Neurostimulation and Mirror Therapy in Traumatic Brachial Plexus Injury N/A
Recruiting NCT06206252 - Can Medical Cannabis Affect Opioid Use?
Completed NCT05103319 - Simultaneous Application of Ketamine and Lidocaine During an Ambulatory Infusion Therapy as a Treatment Option in Refractory Chronic Pain Conditions
Completed NCT03687762 - Back on Track to Healthy Living Study N/A
Completed NCT04171336 - Animal-assisted Therapy for Children and Adolescents With Chronic Pain N/A
Completed NCT03179475 - Targin® for Chronic Pain Management in Patients With Spinal Cord Injury Phase 4
Completed NCT03418129 - Neuromodulatory Treatments for Pain Management in TBI N/A
Completed NCT03268551 - MEMO-Medical Marijuana and Opioids Study
Recruiting NCT06060028 - The Power of Touch. Non-Invasive C-Tactile Stimulation for Chronic Osteoarthritis Pain N/A
Recruiting NCT06204627 - TDCS* and Laterality Trainnning in Patients With Chronic Neck Pain N/A
Completed NCT05496205 - A SAD Study to Evaluate the Safety, Tolerability and PK/PD of iN1011-N17 in Healthy Volunteers Phase 1
Completed NCT00983385 - Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Chronic Low Back Pain Taking Either WHO Step I or Step II Analgesics or no Regular Analgesics Phase 3
Recruiting NCT05118204 - Randomized Trial of Buprenorphine Microdose Inductions During Hospitalization Phase 4
Terminated NCT03538444 - Repetitive Transcranial Magnetic Stimulation for Opiate Use Disorder N/A
Not yet recruiting NCT05812703 - Biometrics and Self-reported Health Changes in Adults Receiving Behavioral Treatments for Chronic Pain